» Articles » PMID: 30587290

Cefiderocol for Treatment of Complicated Urinary Tract Infections

Overview
Date 2018 Dec 28
PMID 30587290
Citations 5
Authors
Affiliations
Soon will be listed here.
Citing Articles

Clinical Distribution and Drug Resistance of in Guangzhou, China from 2017 to 2021.

Lyu J, Chen H, Bao J, Liu S, Chen Y, Cui X J Clin Med. 2023; 12(3).

PMID: 36769837 PMC: 9917919. DOI: 10.3390/jcm12031189.


Clinical experience of cefiderocol.

Farinas M Rev Esp Quimioter. 2022; 35 Suppl 2:35-38.

PMID: 36193983 PMC: 9632058. DOI: 10.37201/req/s02.05.2022.


Acinetobacter baumannii response to cefiderocol challenge in human urine.

Nishimura B, Escalante J, Tuttobene M, Subils T, Mezcord V, Pimentel C Sci Rep. 2022; 12(1):8763.

PMID: 35610334 PMC: 9128776. DOI: 10.1038/s41598-022-12829-7.


Compassionate use of cefiderocol for carbapenem-resistant prosthetic joint infection.

Mabayoje D, NicFhogartaigh C, Cherian B, Tan M, Wareham D JAC Antimicrob Resist. 2021; 3(Suppl 1):i21-i24.

PMID: 34223152 PMC: 8251250. DOI: 10.1093/jacamr/dlab055.


Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.

Mushtaq S, Sadouki Z, Vickers A, Livermore D, Woodford N Antimicrob Agents Chemother. 2020; 64(12).

PMID: 32958717 PMC: 7674041. DOI: 10.1128/AAC.01582-20.